Taft Defeats Injunction Motion Seeking to Remove Client's Hypertension Drug From the Market
November 18, 2021
November 18, 2021
MINNEAPOLIS, Minnesota, Nov. 18 -- Taft, a law firm, issued the following news on Nov. 17, 2021:
Taft Chicago partners Andrew M. Alul and Roshan P. Shrestha, Ph.D., secured a significant litigation victory for generic drug client, Bionpharma Inc. (Bionpharma). Bionpharma markets a 1.0 mg/mL enalapril maleate oral solution as generic to Azurity Pharmaceuticals, Inc.'s (Azurity) Epaned(R), a prescription drug product used to treat hypertension in children and elderly.
Taft Chicago partners Andrew M. Alul and Roshan P. Shrestha, Ph.D., secured a significant litigation victory for generic drug client, Bionpharma Inc. (Bionpharma). Bionpharma markets a 1.0 mg/mL enalapril maleate oral solution as generic to Azurity Pharmaceuticals, Inc.'s (Azurity) Epaned(R), a prescription drug product used to treat hypertension in children and elderly.